Regenerative medicine and bioengineered tissues by Humacyte
University of Texas Medical Branch selects Symvess for surgical advances, Humacyte reports
Humacyte announced that the University of Texas Medical Branch has become the first health system in the Greater Houston metropolitan area to implement its Symvess product. The company also ...
Humacyte conducts first Symvess procedure in Oklahoma
Humacyte announced the successful completion of the first Symvess procedure in Oklahoma. The case was performed by board certified vascular surgeon Dr. Jones Thomas and the INTEGRIS Health Baptist ...
V012 clinical trial from Humacyte targets improved dialysis access for women
Humacyte has initiated V012, the first randomized trial designed to address gender disparities in AV fistula maturation, which is crucial for dialysis access. The company developed this approach ...
Humacyte to present interim Phase 3 V012 trial results for ATEV in women on dialysis
Humacyte will present interim results from its Phase 3 V012 clinical trial evaluating ATEV for hemodialysis access in women. The announcement highlights that women on dialysis are more likely to ...
Symvess demand accelerates as hospital orders jump 44 percent for Humacyte
Humacyte reported a 44 percent increase in the number of hospitals ordering its Symvess product in the third quarter, up from 34 to 49. The company noted growing surgeon interest and greater ...
Humacyte Phase 3 V012 trial results of ATEV in hemodialysis access to be presented
Humacyte announced that results from its Phase 3 V012 trial of ATEV in women requiring hemodialysis access have been accepted for presentation in a late-breaking oral session at ASN Kidney Week ...
First Symvess case deployed at Sacred Heart Emerald Coast
Humacyte announced that the first commercial Symvess procedure in Florida has been performed at Sacred Heart Emerald Coast in Destin. The procedure was carried out by Dr. Geoff Risley of Coastal ...
Humacyte extends Symvess shelf life to 36 months after FDA authorization
Humacyte announced that the U.S. Food and Drug Administration has authorized an extension of the shelf life for Symvess, its acellular tissue engineered vessel, to 36 months. The company stated ...
FDA accepts Humacyte IND for clinical study in cardiovascular tissue engineering
Humacyte announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application to begin the first-in-human clinical trial of the Coronary Tissue ...
Humacyte interim Phase 3 shows significant increase in catheter-free days for female dialysis patients
Humacyte has reached a new clinical milestone in arteriovenous (AV) access for dialysis, unveiling interim Phase 3 (V012) results focused on female patients. The ATEV product achieved the ...
Symvess acellular vessel introduced at live simulation event by Humacyte
Humacyte is hosting a Hands-On Simulation Lab featuring its Symvess acellular tissue engineered vessel-type (ATEV) technology today and tomorrow. The VAM TOUCHPOINT Hands-On / SIM Lab allows ...
Humacyte announces interim results from women-only vascular access study
Humacyte is set to present interim results from its women-only study on arteriovenous (AV) access. The forum will address clear unmet needs in AV access for women, a segment often underrepresented ...
U.S. Veterans Affairs to expand access to Humacyte Symvess implant under new agreement
Humacyte has announced it has secured a contract with the Strategic Acquisition Center of the U.S. Department of Veterans Affairs to provide its Symvess acellular tissue engineered vessel. This ...
Humacyte presents new data on acellular tissue engineered vessels for dialysis access at VASA
Humacyte is set to present new scientific research on acellular tissue engineered vessels at the Vascular Access Society of the Americas (VASA) meeting. The study examines the performance of ...
